Head to Head Survey: Bio-Path (BPTH) & CTI BioPharma (CTIC)

Bio-Path (NASDAQ: BPTH) and CTI BioPharma (NASDAQ:CTIC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Bio-Path has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, CTI BioPharma has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Institutional and Insider Ownership

9.3% of Bio-Path shares are owned by institutional investors. Comparatively, 42.8% of CTI BioPharma shares are owned by institutional investors. 11.2% of Bio-Path shares are owned by insiders. Comparatively, 2.2% of CTI BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Bio-Path and CTI BioPharma’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Path $10,000.00 1,791.72 -$6.75 million ($0.74) -2.14
CTI BioPharma $57.40 million 2.77 -$52.00 million ($1.03) -3.59

Bio-Path has higher earnings, but lower revenue than CTI BioPharma. CTI BioPharma is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bio-Path and CTI BioPharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bio-Path N/A -72.98% -59.29%
CTI BioPharma -96.91% -209.67% -50.35%

Analyst Ratings

This is a breakdown of current recommendations for Bio-Path and CTI BioPharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path 0 0 2 0 3.00
CTI BioPharma 0 0 1 0 3.00

Bio-Path presently has a consensus price target of $17.50, suggesting a potential upside of 1,007.59%. CTI BioPharma has a consensus price target of $7.50, suggesting a potential upside of 102.70%. Given Bio-Path’s higher possible upside, research analysts plainly believe Bio-Path is more favorable than CTI BioPharma.

Summary

Bio-Path beats CTI BioPharma on 10 of the 13 factors compared between the two stocks.

About Bio-Path

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

About CTI BioPharma

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply